AstraZeneca stock falls after FDA panel votes against new cancer drug

May 1, 2026

```json { "title": "FDA Panel Votes Against AstraZeneca's Camizestrant Breast Cancer Drug", "metaDescription": "An FDA advisory panel voted 6-3 against camizestrant for HR+ breast cancer, citing trial design concerns. AstraZeneca shares fell nearly 2% in London.", "content": "<h2>FDA Advisory Panel Votes 6-3 Against AstraZeneca's Camizestrant for Advanced Breast Cancer</h2>AstraZeneca shares fell nearly 2% in London on May 1, 2026, after the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) voted 6 to 3 against the benefit-risk profile of camizestrant for the first-line treatment of HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation. The vote, which took place on April 30, 2026, was a significant setback for a drug the company had projected could generate over $5 billion in peak annual sales.The ODAC's decision concerned New Drug Application (NDA) 220359 — camizestrant tablets in combination with a CDK4/6 inhibitor — submitted by AstraZeneca Pharmaceuticals LP. The panel's objections centered not on the drug's safety or efficacy in absolute terms, but on the design of the pivotal clinical trial used to support the application and its ability to establish clinical benefit in the proposed setting.<h2>What the ODAC Voted On — and Why It Voted No</h2>The application was built on results from the Phase III SERENA-6 trial, data from which were presented at the 2025 ASCO Annual Meeting and simultaneously published in The New England Journal of Medicine. The trial tested a novel clinical strategy: switching patients to camizestrant in combination with a CDK4/6 inhibitor at the moment an ESR1 mutation was detected via circulating tumor DNA testing — before any radiographic evidence of disease progression — a meaningful departure from standard clinical practice.On its face, the SERENA-6 results appeared compelling. Patients who switched to camizestrant experienced a median progression-free survival (PFS) of 16.0 months (95% CI, 12.7–18.2), compared with 9.2 months (95% CI, 7.2–9.5) in the aromatase inhibitor control arm (HR 0.44; P <.00001) — a 56% reduction in the risk of disease progression or death. The trial also showed a median second progression-free survival (PFS2) of 25.7 months for the camizestrant arm versus 19.1 months for the comparator arm.Despite these numbers, the ODAC raised several pointed concerns. According to the FDA's own briefing document, the committee questioned the clinical meaningfulness of a PFS improvement measured from a nonstandard time zero, the lack of evidence that switching at ESR1 mutation detection is superior to switching at radiographic progression, and the immaturity of overall survival (OS) data — arguably the most definitive measure of benefit in oncology trials.ODAC member Karla Ballman, PhD, of Mayo Clinic, articulated the panel's central hesitation: "I think that it has not been proven that if you treat at the time of a mutation, you get the most benefit vs waiting until radiographic progression."The FDA's own clinical team leader for the application, Mirat Shah, MD, of the Division of Oncology 1, Office of Oncologic Diseases, was similarly direct: "The treatment paradigm evaluated in SERENA-6 is experimental and does not represent standard of care for patients with [HR+] metastatic breast cancer."ODAC member Michael Kelley, M.D., of Duke University Medical Center, framed the issue in terms of what the trial actually compared: "What is being asked here is early versus late. It's not early versus never, and that is what essentially was done."<h2>Safety Concerns Added to the Committee's Reservations</h2>Beyond trial design, the ODAC also reviewed camizestrant's safety profile. As an investigational, potent, next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist, camizestrant is associated with unique toxicities including visual disturbances (photopsia) and cardiotoxicity in the form of bradycardia and QT prolongation. Notably, one nonfatal case of Torsade de Pointes occurred in a Phase 1 trial when camizestrant was combined with ribociclib — one of the CDK4/6 inhibitors included in the proposed combination regimen.These safety signals, while not the primary driver of the negative vote, added complexity to the committee's assessment of a benefit-risk profile where the clinical benefit itself remained contested.<h2>AstraZeneca Responds — and Looks to Global Filings and Future Data</h2>AstraZeneca expressed disappointment with the outcome but stopped short of withdrawing its application or abandoning the program. Susan Galbraith, Executive Vice President, Oncology Haematology R&D at AstraZeneca, stated: "New innovations and novel treatment strategies that provide benefit to patients are required to drive advances in this 1st-line setting, and so we are disappointed with the mixed outcome of today's ODAC meeting."Kevin Kalinsky, MD, MS, FASCO, Division Director of Medical Oncology at the Winship Cancer Institute of Emory University and an investigator for the SERENA-6 trial, echoed that sentiment: "Today's recommendation by the ODAC is disappointing, as new options and innovative treatment strategies which address emerging resistance ahead of disease progression and deterioration in quality of life are needed in the 1st-line setting."Regulatory applications for camizestrant in this setting are also currently under review in the EU, Japan, and several other countries, meaning the FDA's advisory panel vote does not close the door on the drug globally. AstraZeneca stated it will continue working with the FDA following the ODAC recommendation.<h2>Wall Street's Reaction: Contained, But Watchful</h2>Despite the share price dip, analyst reaction was measured. Jefferies analyst Michael Leuchten maintained a 'Buy' rating and $243 price target on AstraZeneca following the committee vote, describing the negative vote as unsurprising. JPMorgan called the ODAC decision a 'minor negative,' noting that camizestrant would represent only about 1% of AstraZeneca's overall valuation. For context, AstraZeneca reported total revenue of $58.74 billion in 2025, and the company is targeting $80 billion in revenue by 2030, with up to 20 new medicine launches planned by that year.Leerink analysts, while noting the setback, highlighted a pathway forward: "The panelists' concerns were focused on the trial design, its endpoints, and its ability to establish clinical benefit. This leaves the door open for other (camizestrant) programs."Morgan Stanley analysts led by Sarita Kapila offered a more cautious read: "We see a decreased likelihood of approval in the SERENA-6 setting following the 6–3 negative ODAC vote, though approval remains possible."The distinction analysts drew repeatedly was that the ODAC's objections were methodological — rooted in how the SERENA-6 trial was designed and what question it was asking — rather than a fundamental rejection of camizestrant as a therapeutic agent. That framing keeps the door open for approval based on data from other ongoing studies, such as SERENA-4, which is evaluating camizestrant in a different clinical context.<h2>Why This Matters: A High-Stakes Bet on Precision Oncology</h2>The camizestrant case is a window into one of the most active debates in modern oncology: when, exactly, should treatment be changed in response to emerging molecular resistance? The SERENA-6 trial was built on the premise that detecting an ESR1 mutation in circulating tumor DNA — a marker of emerging resistance to aromatase inhibitors — should trigger an immediate treatment switch, even before the patient shows signs of progression on imaging. It was a precision medicine argument: act on the molecular signal, not the clinical one.The ODAC was not persuaded that this premise had been adequately proven. The panel's concern was not that early switching is wrong in principle, but that the trial did not demonstrate it is better than switching at the point of radiographic progression — the standard approach. Without that head-to-head comparison, the committee found the benefit-risk calculus unconvincing, particularly given the immature overall survival data and the drug's cardiotoxicity signals.This is also a notable moment for the FDA advisory committee process itself. According to Fierce Biotech, the April 30, 2026 ODAC meeting was the first FDA advisory committee meeting for a drug in approximately nine months, following a prolonged hiatus. The return of the ODAC to active deliberation — and its willingness to issue a firm 6-3 rebuke of a well-resourced NDA backed by Phase III data published in the New England Journal of Medicine — signals that the committee is prepared to apply rigorous scrutiny to novel trial designs, not just safety profiles.It is also worth noting that on the same day ODAC voted against camizestrant, the committee voted in favor of AstraZeneca's Truqap (capivasertib) for metastatic prostate cancer — a reminder that the camizestrant decision was specific to the evidence package presented for this particular indication, not a broader judgment on AstraZeneca's oncology pipeline.<h2>What Happens Next</h2>The FDA is not bound by ODAC recommendations, and approval of NDA 220359 remains possible. However, the 6-3 vote against the benefit-risk profile creates a more difficult regulatory path for this specific indication. AstraZeneca has stated it will continue engaging with the FDA, and international regulatory reviews in the EU, Japan, and other markets remain ongoing.The broader camizestrant program is not contingent solely on the SERENA-6 application. Ongoing trials in other settings — including SERENA-4 — may generate data that more clearly satisfy regulators' demand for evidence that early intervention improves outcomes compared to standard-of-care timing. Analysts at Leerink noted that the ODAC's concerns, being focused on trial design rather than the drug itself, leave those other programs intact.For patients with HR-positive, HER2-negative advanced breast cancer and emergent ESR1 mutations, the vote means that camizestrant will not be available through this regulatory pathway in the near term — at least in the United States. The question of whether to treat at molecular detection or wait for radiographic progression remains, for now, unanswered by the clinical evidence to the FDA's satisfaction.For more tech news, visit our <a href="/news">news section</a>.", "excerpt": "The FDA's Oncologic Drugs Advisory Committee voted 6 to 3 against AstraZeneca's camizestrant for HR-positive, HER2-negative advanced breast cancer on April 30, 2026, citing concerns about trial design and immature survival data. AstraZeneca shares fell nearly 2% in London following the vote. Analysts described the setback as contained but noted a decreased likelihood of approval in this specific setting.", "keywords": ["camizestrant", "AstraZeneca", "FDA advisory committee", "ODAC", "HR-positive breast cancer", "ESR1 mutation", "SERENA-6 trial", "SERD breast cancer treatment"], "slug": "fda-panel-votes-against-astrazeneca-camizestrant-breast-cancer" } ```

← Back to Tech News

More Tech News

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

FDA Approves First Gene Therapy to Restore Hearing

The Best Personal AI for Health in 2026. An Honest Guide.